FibroNox, Inc.

FibroNox is focused on developing patented first-in-class therapeutics to treat and reverse life-threatening fibrotic diseases. FibroNox has pioneered the development of selective Nox4 inhibitors and Nrf2 activators that have shown robust protection from fibrosis development and promoted the reversal of age-associated established fibrosis. FibroNox’s initial focus is treating idiopathic pulmonary fibrosis and fibrosis in Duchenne muscular dystrophy. FibroNox’s therapeutics offer the opportunity to reverse age-associated established fibrosis, representing the holy grail for more effective strategies to treat fibrotic diseases.